A chimeric antigen receptor-based cellular safeguard mechanism for selective

Adoptive immunotherapy based on chimeric antigen receptor (CAR)-engineered T cells has exhibited impressive clinical efficacy in treating B-cell malignancies. However, the potency of CAR-T cells carriethe potential for significant on-target/off-tumor toxicities when target antigens are shared with healthy cells, necessitating the development of complementary safety measures. In this context, there is a need to selectively eliminate therapeutically administered CAR-T cells, especially to revert long-term CAR-T cell-related side effects. To address this, we have developed an effective cellular-based safety mechanism to specifically target and eliminate the transferred CAR-T cells. As proof-of-principle, we have designed a secondary CAR (

Informations de copyright

Copyright © 2024 Svec, Dötsch, Warmuth, Trebo, Fräßle, Riddell, Jäger, D’Ippolito and Busch.

Déclaration de conflit d'intérêts

DB is co-founder of STAGE Cell Therapeutics GmbH now Juno Therapeutics, a Bristol-Myers Squibb Company and T Cell Factory B.V. now Kite/a Gilead Company. DB has a consulting contract with and receives sponsored research support from Juno Therapeutics/BMS. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.